Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences in May

Rhea-AI Summary

Foghorn Therapeutics (Nasdaq:FHTX), a clinical-stage biotechnology company focused on oncology, will participate in three investor conferences in May 2026.

Management will attend the H.C. Wainwright Bioconnect Investor Conference, 2026 Stifel Virtual Targeted Oncology Forum, and TD Cowen Oncology Innovation Summit, including presentations and one-on-one investor meetings.

News Market Reaction – FHTX

-2.08%

-2.08% Session close to close

In the May 12 session, FHTX declined 2.08%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WATERTOWN, Mass., May 12, 2026 (GLOBE NEWSWIRE) -- Foghorn^® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the H.C. Wainwright 4th Annual Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA. With an initial focus in oncology, Foghorn’s Gene Traffic Control® platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

H.C. Wainwright 4th Annual Bioconnect Investor Conference at Nasdaq

• Management will participate in one-on-one meetings on May 19, 2026
  
  

2026 Stifel Virtual Targeted Oncology Forum 

• Presentation: Wednesday, May 20, 2026, at 11:00 a.m. EDT
• Presenter: Adrian Gottschalk, President and Chief Executive Officer
• Management will also participate in one-on-one meetings
  
  

TD Cowen 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA (Virtual)

• Presentation: Tuesday, May 26, 2026, at 8:30 a.m. EDT
• Presenter: Adrian Gottschalk, President and Chief Executive Officer

About Foghorn Therapeutics
Foghorn^® Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control^® platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at www.foghorntx.com for more information on the Company, and follow us on X and LinkedIn.

Contact:
Karin Hellsvik, Foghorn Therapeutics Inc.
khellsvik@foghorntx.com

FAQ

What investor conferences will Foghorn Therapeutics (FHTX) attend in May 2026?

Foghorn Therapeutics will attend three oncology-focused investor events in May 2026. According to Foghorn Therapeutics, management will join the H.C. Wainwright Bioconnect Investor Conference, the 2026 Stifel Virtual Targeted Oncology Forum, and the TD Cowen Oncology Innovation Summit.

When is Foghorn Therapeutics presenting at the 2026 Stifel Virtual Targeted Oncology Forum?

Foghorn Therapeutics will present on May 20, 2026, at 11:00 a.m. EDT. According to Foghorn Therapeutics, President and CEO Adrian Gottschalk will present and management will also participate in one-on-one investor meetings during the virtual forum.

What is Foghorn Therapeutics doing at the H.C. Wainwright Bioconnect Investor Conference in May 2026?

Foghorn Therapeutics management will participate in one-on-one meetings on May 19, 2026. According to Foghorn Therapeutics, these meetings at the H.C. Wainwright 4th Annual Bioconnect Investor Conference at Nasdaq offer direct engagement with institutional investors.

When will Foghorn Therapeutics present at the TD Cowen Oncology Innovation Summit in 2026?

Foghorn Therapeutics will present on May 26, 2026, at 8:30 a.m. EDT. According to Foghorn Therapeutics, Adrian Gottschalk, President and Chief Executive Officer, will present at this virtual TD Cowen 7th Annual Oncology Innovation Summit.

Who will present for Foghorn Therapeutics (FHTX) at the May 2026 investor conferences?

Adrian Gottschalk, President and Chief Executive Officer, will present at key May 2026 events. According to Foghorn Therapeutics, he is scheduled as presenter at both the Stifel Virtual Targeted Oncology Forum and the TD Cowen Oncology Innovation Summit.

What is the focus of Foghorn Therapeutics’ platform discussed at these May 2026 conferences?

Foghorn Therapeutics focuses on correcting abnormal gene expression with its Gene Traffic Control platform. According to Foghorn Therapeutics, this platform supports a broad oncology pipeline aimed at treating serious diseases across a wide spectrum of indications.